[A23-94] Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Benefit assessment according to §35a Social Code Book V
Last updated 21.03.2024
Project no.:
A23-94
Commission:
Commission awarded on 29.10.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adjuvant treatment of stage IIB or IIC melanoma after complete resection in adults and adolescents 12 years of age and older
- Adults: hint of minor added benefit
- Adolescents 12 years of age and older: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-94_en
Federal Joint Committee (G-BA)
2024-03-21 A G-BA decision was published.